Insightful Analysis on Economics, Markets & Global Affairs

Affirm's best quarter ever sent its stock down 4%. The reason is what comes next: a physical card with rewards math that CEO Max Levchin calls "really, really hard science."

Phibro Animal Health posted a strong first full year after its big acquisition, but thin cash flow and slowing growth raise real questions about what comes next.

Medtronic and its newly spun-off diabetes arm Minimed both raised their full-year outlooks after stronger-than-expected sales across the board.

Teva wants worldwide rights to an FDA-reviewed agitation drug, picking it up from a bankruptcy sale for up to $125 million.

ONEOK is buying Brazos Midstream's Permian pipeline assets for $4.425bn, betting that America's most productive oil patch still has years of growth ahead.

Goldman Sachs now expects U.S. diesel refining margins to hit $63 a barrel by 2027, double its earlier forecast, as war damage to Middle East and Russian refineries bites hard.

Miniso is breaking records in China while its global expansion quietly bleeds profit. The two stories are heading toward a reckoning.

Asian refiners from China to South Korea are buying Argentine crude to avoid the Middle East, reshaping global oil trade in real time.